Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
group_1_presentation_3_-_parkinson_s_disease [2017/12/02 12:25]
tariqm2 [Epidemiology]
group_1_presentation_3_-_parkinson_s_disease [2018/01/25 15:18] (current)
Line 1: Line 1:
 ======= Coronary Heart Disease ======= ======= Coronary Heart Disease =======
 +{{::​coronary_heart_disease_.pptx|}}
  
 ====== Introduction ====== ====== Introduction ======
Line 31: Line 32:
  
 {{ :​screen_shot_2017-12-02_at_12.01.58_am.png |}} {{ :​screen_shot_2017-12-02_at_12.01.58_am.png |}}
-**Figure 2:** Illustrates the observational pattern of the Electrocardiograph when the heart'​s electrical activity is modified. Top Left: Normal ECG Pattern, with baseline electrical levels. Top Right: Non-ST Elevation Myocardial Infarction, when there is partial blockage of the artery, the heart will show an ECG pattern with ST-depression. Bottom Right: ST-Elevation Myocardial Infarction, when there is a complete blockage of the artery, the heart will show an ECG pattern of ST-Elevation. Bottom Right: ST-Depression with T Inversion(Klabunde,​ 2016). ​+**Figure 2: Illustrates the observational pattern of the Electrocardiograph when the heart'​s electrical activity is modified. Top Left: Normal ECG Pattern, with baseline electrical levels. Top Right: Non-ST Elevation Myocardial Infarction, when there is partial blockage of the artery, the heart will show an ECG pattern with ST-depression. Bottom Right: ST-Elevation Myocardial Infarction, when there is a complete blockage of the artery, the heart will show an ECG pattern of ST-Elevation. Bottom Right: ST-Depression with T Inversion(Klabunde,​ 2016).**
  
 ---- ----
Line 39: Line 40:
  
 {{ ::​screen_shot_2017-12-02_at_12.06.15_am.png |}} {{ ::​screen_shot_2017-12-02_at_12.06.15_am.png |}}
-**Figure 3:** Demonstrating Cardiac Troponin-T bound to actin filaments in cardiac muscle(Melanson et al., 2007).+**Figure 3: Demonstrating Cardiac Troponin-T bound to actin filaments in cardiac muscle(Melanson et al., 2007).**
  
 {{ ::​screen_shot_2017-12-02_at_12.07.53_am.png |}} {{ ::​screen_shot_2017-12-02_at_12.07.53_am.png |}}
-**Figure 4:** Acute myocardial infarction illustrated by soluble Troponin-T levels as high as 50 ug/L. B: Minor myocardial infarction as seen with drastically lower levels of Troponin-T in the blood, with only over 0.05 ug/L after 24-48 hours(Melanson et al., 2007).+**Figure 4: Acute myocardial infarction illustrated by soluble Troponin-T levels as high as 50 ug/L. B: Minor myocardial infarction as seen with drastically lower levels of Troponin-T in the blood, with only over 0.05 ug/L after 24-48 hours(Melanson et al., 2007).**
  
 ---- ----
Line 50: Line 51:
  
 {{ :​diagnosis.jpg |}} {{ :​diagnosis.jpg |}}
-**Figure 5:** Displaying cardiac catheterization beginning from a femoral artery entrance, making its way up the coronary artery to indicate the location of the plaque buildup, as well as take inter-arterial illustrations of the heart via a X-ray dye, thus conducting an angiogram(Robinson,​ 2011).+**Figure 5: Displaying cardiac catheterization beginning from a femoral artery entrance, making its way up the coronary artery to indicate the location of the plaque buildup, as well as take inter-arterial illustrations of the heart via a X-ray dye, thus conducting an angiogram(Robinson,​ 2011).**
 ====== Pathophysiology ====== ====== Pathophysiology ======
  
Line 67: Line 68:
  
 {{ :​screen_shot_2017-11-28_at_3.21.04_am.png?​300 |}} {{ :​screen_shot_2017-11-28_at_3.21.04_am.png?​300 |}}
-**Figure 6:** Demonstrates the last stage of progression of atherosclerosis in which there is thrombus formation (Radar and Daugherty, 2008).+**Figure 6: Demonstrates the last stage of progression of atherosclerosis in which there is thrombus formation (Radar and Daugherty, 2008).**
 ====== Treatment ====== ====== Treatment ======
  
Line 85: Line 86:
  
 {{ :​screen_shot_2017-12-01_at_11.13.45_pm.png?​200 |}} {{ :​screen_shot_2017-12-01_at_11.13.45_pm.png?​200 |}}
-**Figure 7:** Shows the mechanism of action of aspirin as an anti-platelet drug (Frishman et al., 2005)+**Figure 7: Shows the mechanism of action of aspirin as an anti-platelet drug (Frishman et al., 2005).**
  
 ---- ----
Line 93: Line 94:
  
 {{ :​screen_shot_2017-11-27_at_12.06.14_am.png |}} {{ :​screen_shot_2017-11-27_at_12.06.14_am.png |}}
-**Figure 8:** Demonstrates beta-blockers as an antagonist, and its effects by lowering heart workload in a patient with coronary heart disease (Frishman et al., 2005). ​+**Figure 8: Demonstrates beta-blockers as an antagonist, and its effects by lowering heart workload in a patient with coronary heart disease (Frishman et al., 2005).**
  
 ---- ----
Line 101: Line 102:
  
 {{ :​screen_shot_2017-11-27_at_12.06.29_am.png?​300 |}} {{ :​screen_shot_2017-11-27_at_12.06.29_am.png?​300 |}}
-**Figure 9:** Illustrates nitroglycerin as a precursor for nitric oxide, and its direct activation of pathways to allow vasodilation(Kukovetz et al., 1987). ​+**Figure 9: Illustrates nitroglycerin as a precursor for nitric oxide, and its direct activation of pathways to allow vasodilation(Kukovetz et al., 1987).**
  
 ---- ----
Line 109: Line 110:
  
 {{ :​stents.jpeg |}} {{ :​stents.jpeg |}}
-**Figure 10:** Illustrates a step-by-step procedure of angioplasty,​ which is a medicinal procedure for coronary artery disease (National Heart, Lung, and Blood Institute, 2016).+**Figure 10: Illustrates a step-by-step procedure of angioplasty,​ which is a medicinal procedure for coronary artery disease (National Heart, Lung, and Blood Institute, 2016).**
 ====== Future Therapeutics ====== ====== Future Therapeutics ======
  
Print/export
QR Code
QR Code group_1_presentation_3_-_parkinson_s_disease (generated for current page)